These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
231 related items for PubMed ID: 7532715
1. Total parenteral nutrition modifies the acute phase response to Crohn's disease. Carlson GL, Gray P, Barber D, Shaffer JL, Mughal M, Irving MH. J R Coll Surg Edinb; 1994 Dec; 39(6):360-4. PubMed ID: 7532715 [Abstract] [Full Text] [Related]
2. Effect of total parenteral nutrition on serum concentrations of eight proteins in Crohn's disease. Jacobson S, Kallner A. Am J Gastroenterol; 1984 Jul; 79(7):501-5. PubMed ID: 6430066 [Abstract] [Full Text] [Related]
3. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Niederau C, Backmerhoff F, Schumacher B, Niederau C. Hepatogastroenterology; 1997 Jul; 44(13):90-107. PubMed ID: 9058126 [Abstract] [Full Text] [Related]
4. [Serum acute phase proteins for determining disease activity of ulcerative colitis and Crohn disease]. Vucelić B, Milicić D, Krznarić Z, Korać B, Sentić M, Hadzić N, Stavljenić A, Cvorisćec D. Acta Med Austriaca; 1991 Jul; 18(4):100-5. PubMed ID: 1722373 [Abstract] [Full Text] [Related]
5. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Bernstein CN, Papineau N, Zajaczkowski J, Rawsthorne P, Okrusko G, Blanchard JF. Am J Gastroenterol; 2000 Mar; 95(3):677-83. PubMed ID: 10710056 [Abstract] [Full Text] [Related]
6. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Henriksen M, Jahnsen J, Lygren I, Stray N, Sauar J, Vatn MH, Moum B, IBSEN Study Group. Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104 [Abstract] [Full Text] [Related]
7. Biological measurements of Crohn's disease activity--a reassessment. André C, Descos L, André F, Vignal J, Landais P, Fermanian J. Hepatogastroenterology; 1985 Jun; 32(3):135-7. PubMed ID: 2410345 [Abstract] [Full Text] [Related]
8. Crohn's disease activity: assessment by factor VIII coagulation proteins. Zielen S, Bender SW, Kreuz W, Posselt HG, Solem E, Scharrer I. J Pediatr Gastroenterol Nutr; 1985 Oct; 4(5):730-4. PubMed ID: 3930684 [Abstract] [Full Text] [Related]
9. [Increase of resting energy expenditure during flare-ups in Crohn disease]. Rigaud D, Cerf M, Angel Alberto L, Sobhani I, Carduner MJ, Mignon M. Gastroenterol Clin Biol; 1993 Oct; 17(12):932-7. PubMed ID: 8125226 [Abstract] [Full Text] [Related]
10. Therapeutic efficacy of infliximab on active Crohn's disease under nutritional therapy. Matsumoto T, Iida M, Kohgo Y, Imamura A, Kusugami K, Nakano H, Fujiyama Y, Matsu T, Hibi T. Scand J Gastroenterol; 2005 Dec; 40(12):1423-30. PubMed ID: 16316890 [Abstract] [Full Text] [Related]
11. Correlation between levels of C-reactive protein and clinical activity in Crohn's disease. Karoui S, Ouerdiane S, Serghini M, Jomni T, Kallel L, Fekih M, Boubaker J, Filali A. Dig Liver Dis; 2007 Nov; 39(11):1006-10. PubMed ID: 17889628 [Abstract] [Full Text] [Related]
12. Total enteral nutrition versus total parenteral nutrition after major torso injury: attenuation of hepatic protein reprioritization. Peterson VM, Moore EE, Jones TN, Rundus C, Emmett M, Moore FA, McCroskey BL, Haddix T, Parsons PE. Surgery; 1988 Aug; 104(2):199-207. PubMed ID: 2456626 [Abstract] [Full Text] [Related]
13. [Effect of parenteral nutrition on serum proteins in patients with Crohn disease]. Meryn S, Lochs H, Pötzi R, Abel B. Infusionsther Klin Ernahr; 1982 Jun; 9(3):149-52. PubMed ID: 6809621 [Abstract] [Full Text] [Related]
14. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease. Gao Q, Hogezand RA, Lamers CB, Verspaget HW. Aliment Pharmacol Ther; 2004 Sep 01; 20(5):585-92. PubMed ID: 15339330 [Abstract] [Full Text] [Related]
15. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Martínez-Borra J, López-Larrea C, González S, Fuentes D, Dieguez A, Deschamps EM, Pérez-Pariente JM, López-Vázquez A, de Francisco R, Rodrigo L. Am J Gastroenterol; 2002 Sep 01; 97(9):2350-6. PubMed ID: 12358255 [Abstract] [Full Text] [Related]
16. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ, International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. Gastroenterology; 2007 May 01; 132(5):1672-83. PubMed ID: 17484865 [Abstract] [Full Text] [Related]
17. Levels of portal and systemic blood cytokines after colectomy in patients with carcinoma or Crohn's disease. Riché F, Dosquet C, Panis Y, Valleur P, Laisné MJ, Briard C, Wautier JL. J Am Coll Surg; 1995 Jun 01; 180(6):718-24. PubMed ID: 7773486 [Abstract] [Full Text] [Related]
18. [Total parenteral nutrition in inflammatory bowel disease. An evaluation of its clinical response]. Takagi Y, Nezu R, Kubota A, Kamata S, Itakura T, Okada A. Nihon Geka Gakkai Zasshi; 1984 Sep 01; 85(9):1006-9. PubMed ID: 6438479 [Abstract] [Full Text] [Related]
19. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S. Dig Liver Dis; 2004 May 01; 36(5):342-7. PubMed ID: 15191204 [Abstract] [Full Text] [Related]
20. Clinically active Crohn's disease in the presence of a low C-reactive protein. Florin TH, Paterson EW, Fowler EV, Radford-Smith GL. Scand J Gastroenterol; 2006 Mar 01; 41(3):306-11. PubMed ID: 16497618 [Abstract] [Full Text] [Related] Page: [Next] [New Search]